Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
Pratt
Craig M
CM
Department of Cardiology, Methodist DeBakey Heart and Vascular Center, Methodist Research Institute, Houston, Texas, USA. cpratt@tmhs.org
Roy
Denis
D
Torp-Pedersen
Christian
C
Wyse
D George
DG
Toft
Egon
E
Juul-Moller
Steen
S
Retyk
Enrique
E
Drenning
David Humphrey
DH
D000840:Anisoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D001282:Atrial Flutter / Q000188:drug therapy / Q000503:physiopathology; D016009:Chi-Square Distribution; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011446:Prospective Studies; D011759:Pyrrolidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000840:Anisoles; D000889:Anti-Arrhythmia Agents; D010919:Placebos; D011759:Pyrrolidines; C524581:vernakalant